US 12,194,039 B2
Methods of treating heart failure by administering omecamtiv mecarbil
Narimon Honarpour, Thousand Oaks, CA (US); and Fady Malik, Burlingame, CA (US)
Assigned to AMGEN INC, Thousand Oaks, CA (US); and CYTOKINETICS, INC., South San Francisco, CA (US)
Filed by Cytokinetics, Inc., South San Francisco, CA (US); and Amgen Inc., Thousand Oaks, CA (US)
Filed on Nov. 11, 2021, as Appl. No. 17/454,592.
Claims priority of provisional application 63/203,436, filed on Jul. 22, 2021.
Claims priority of provisional application 63/202,873, filed on Jun. 28, 2021.
Claims priority of provisional application 63/187,084, filed on May 11, 2021.
Claims priority of provisional application 63/154,077, filed on Feb. 26, 2021.
Claims priority of provisional application 63/112,995, filed on Nov. 12, 2020.
Prior Publication US 2022/0184068 A1, Jun. 16, 2022
Int. Cl. A61K 31/497 (2006.01); A61N 1/39 (2006.01)
CPC A61K 31/497 (2013.01) [A61N 1/3956 (2013.01)] 30 Claims
 
1. A method of treating heart failure in a patient who has a left ventricular ejection fraction (LVEF) of less than or equal to 28% at baseline, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, a salt, or a salt of a hydrate thereof.